≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Nezelof syndrome

DOID EFO Endpoint Browser PheWeb

D3_NEFELOF

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — D81.4
  • Cause of death: ICD-10 — D81.4

2 out of 7 registries used, show all original rules.

152

4. Check minimum number of events

None

152

5. Include endpoints

None

152

6. Filter based on genotype QC (FinnGen only)

149

Control definitions (FinnGen only)

Control exclude
D3_IMMUNEMECHANISM

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
D81
Name in latin
Syndroma Nezelof

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 1192 627 560
Only index persons 1015 541 474
Unadjusted period prevalence (%)
Whole population 0.02 0.02 0.02
Only index persons 0.02 0.02 0.02
Median age at first event (years)
Whole population 57.80 56.96 58.61
Only index persons 56.18 55.27 57.21

-FinnGen-

Key figures

All Female Male
Number of individuals 149 87 62
Unadjusted period prevalence (%) 0.03 0.03 0.03
Median age at first event (years) 54.96 51.55 59.75

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
152
Matched controls
1520
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D81.4
ICD-10 Finland
Nezelof syndrome
+∞
219.7
152
*
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
26.5
98.3
99
100
Y83
ICD-10 Finland
Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
16.1
57.6
60
59
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
7.9
19.1
29
44
WX408
NOMESCO Finland
General anesthesy, balanced
4.4
17.8
69
242
ZXE20
NOMESCO Finland
More than three and less than five hours
5.0
17.0
45
117
ZXD05
NOMESCO Finland
Urgent procedure
4.0
15.9
79
326
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
4.5
15.6
48
140
ZXE10
NOMESCO Finland
More than one and less than three hours
3.7
14.1
83
376
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.0
13.4
49
161
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.8
12.5
50
174
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
9.7
11.0
22
26
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.2
10.8
33
94
J01MA12
ATC
levofloxacin; systemic
3.4
10.3
48
182
J01FF01
ATC
clindamycin; systemic
3.0
9.9
63
287
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
4.3
9.5
27
72
WX404
NOMESCO Finland
Intravenous generell anesthesy
3.2
9.4
49
198
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.9
8.6
28
83
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
4.0
8.6
27
78
ZXA00
NOMESCO Finland
Right side
2.8
8.5
61
292
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
3.7
8.4
30
95
M01AH01
ATC
celecoxib; oral
3.2
8.3
41
159
Z3226
NOMESCO Finland
Physiotherapist
3.1
8.2
44
179
WX002
NOMESCO Finland
Sedation and analgesia
3.0
8.0
44
181
ZXD10
NOMESCO Finland
Scheduled procedure
2.6
7.8
74
404
T81.3
ICD-10 Finland
Disruption of operation wound, not elsewhere classified
10.9
7.7
14
14
X59
ICD-10 Finland
Exposure to unspecified factor
2.9
7.7
44
185
TPH04
NOMESCO Finland
Cathetrisation of vein
2.8
7.4
49
223
ZXD35
NOMESCO Finland
Usual procedure
7.6
7.2
16
23
Y84
ICD-10 Finland
Other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
14.7
7.0
11
8
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.6
6.9
25
79
QDG20
NOMESCO Finland
Operation for chronic ulcer or fistula of skin of lower limb
42.0
6.8
8
*
ZZA00
NOMESCO Finland
Split skin graft
8.4
6.8
14
18
ZXE30
NOMESCO Finland
More than five and less than seven hours
6.2
6.7
17
30
N02AX02
ATC
tramadol; systemic, rectal
2.4
6.6
83
505
J01DA01
ATC
[U] cefalexin
2.6
6.6
112
781
Y88.3
ICD-10 Finland
Sequelae of surgical and medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
8.0
6.6
14
19
R50.9
ICD-10 Finland
Fever, unspecified
2.9
6.4
36
149
Z3231
NOMESCO Finland
Registered nurse
2.5
6.4
58
305
N03AX16
ATC
[U] pregabalin
2.6
6.3
47
224
ZXA05
NOMESCO Finland
Left side
2.5
6.3
53
268
A10AE04
ATC
insulin glargine; parenteral
3.5
6.3
23
73
WZC10
NOMESCO Finland
Written specialist consultation based on a referral from a dentist or a physician
6.3
6.0
15
26

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Outpatient Visit
OP [9202]
1.2e+00
2.1e+00
2.5e+00
4.5e+00
2.4e+00
2.0e+00
1.3e+00
cases:79.61%
controls:53.09%
cases:80.26%
controls:33.49%
cases:55.92%
controls:9.08%
cases:22.37%
controls:0.33%
cases:51.66%
controls:8.82%
cases:80.95%
controls:35.83%
cases:88.41%
controls:67.58%
121
807
31
713
122
509
30
1011
85
138
67
1382
34
5
118
1515
78
134
73
1386
119
540
28
967
122
982
16
471
Outpatient Hospital
22 [8756]
8.9e-01
2.3e+00
4.5e+00
1.0e+50
2.4e+00
1.6e+00
1.4e+00
cases:44.74%
controls:24.87%
cases:48.68%
controls:8.75%
cases:51.32%
controls:1.18%
cases:18.42%
controls:0.00%
cases:11.92%
controls:1.18%
cases:31.29%
controls:8.69%
cases:57.97%
controls:25.40%
68
378
84
1142
74
133
78
1387
78
18
74
1502
28
0
124
1520
18
18
133
1502
46
131
101
1376
80
369
58
1084
Inpatient Hospital
21 [8717]
7.6e-01
2.1e+00
4.2e+00
—
2.6e+00
1.5e+00
1.1e+00
cases:53.29%
controls:34.87%
cases:55.92%
controls:13.22%
cases:57.89%
controls:2.04%
—
—
cases:23.18%
controls:2.24%
cases:40.14%
controls:13.14%
cases:60.87%
controls:34.55%
81
530
71
990
85
201
67
1319
88
31
64
1489
—
35
34
116
1486
59
198
88
1309
84
502
54
951
Office Visit
OMOP4822458 [581477]
9.6e-01
2.1e+00
3.1e+00
1.0e+50
2.9e+00
1.7e+00
1.1e+00
cases:15.13%
controls:6.38%
cases:19.08%
controls:2.89%
cases:6.58%
controls:0.33%
cases:4.61%
controls:0.00%
cases:7.95%
controls:0.46%
cases:12.24%
controls:2.46%
cases:21.74%
controls:8.40%
23
97
129
1423
29
44
123
1476
10
5
142
1515
7
0
145
1520
12
7
139
1513
18
37
129
1470
30
122
108
1331
Orthopedic Surgery
20 [38004465]
1.3e+00
1.8e+00
3.4e+00
1.0e+50
2.6e+00
1.3e+00
1.1e+00
cases:25.66%
controls:8.22%
cases:17.76%
controls:3.49%
cases:9.21%
controls:0.33%
cases:6.58%
controls:0.00%
cases:6.62%
controls:0.53%
cases:14.97%
controls:4.38%
cases:30.43%
controls:12.87%
39
125
113
1395
27
53
125
1467
14
5
138
1515
10
0
142
1520
10
8
141
1512
22
66
125
1441
42
187
96
1266
cefalexin; oral
J01DB01 [21602870]
7.4e-01
1.5e+00
3.6e+00
—
3.4e+00
1.3e+00
8.5e-01
cases:43.42%
controls:26.84%
cases:32.24%
controls:9.41%
cases:20.39%
controls:0.72%
—
—
cases:23.84%
controls:1.05%
cases:27.21%
controls:8.96%
cases:49.28%
controls:29.39%
66
408
86
1112
49
143
103
1377
31
11
121
1509
—
36
16
115
1504
40
135
107
1372
68
427
70
1026
General Surgery
2 [38004447]
7.7e-01
2.0e+00
3.3e+00
1.0e+50
2.8e+00
1.7e+00
8.3e-01
cases:40.13%
controls:23.68%
cases:34.87%
controls:7.04%
cases:26.97%
controls:1.38%
cases:34.87%
controls:0.00%
cases:19.21%
controls:1.45%
cases:30.61%
controls:7.43%
cases:37.68%
controls:20.85%
61
360
91
1160
53
107
99
1413
41
21
111
1499
53
0
99
1520
29
22
122
1498
45
112
102
1395
52
303
86
1150
Emergency Room Visit
ER [9203]
6.8e-01
1.6e+00
3.5e+00
—
2.5e+00
1.4e+00
9.4e-01
cases:42.76%
controls:27.43%
cases:38.16%
controls:10.79%
cases:29.61%
controls:1.32%
—
—
cases:15.89%
controls:1.51%
cases:33.33%
controls:11.15%
cases:57.97%
controls:34.96%
65
417
87
1103
58
164
94
1356
45
20
107
1500
—
24
23
127
1497
49
168
98
1339
80
508
58
945
Medical doctor
Z2221 [2001311556]
1.1e+00
2.0e+00
—
1.0e+50
3.2e+00
2.1e+00
1.3e+00
cases:10.53%
controls:3.88%
cases:13.16%
controls:1.97%
—
—
cases:5.26%
controls:0.00%
cases:7.28%
controls:0.33%
cases:11.56%
controls:1.53%
cases:15.22%
controls:4.61%
16
59
136
1461
20
30
132
1490
—
8
0
144
1520
11
5
140
1515
17
23
130
1484
21
67
117
1386
Obstetrics / Gynecology
16 [38004461]
6.7e-01
1.4e+00
3.6e+00
—
2.8e+00
1.2e+00
3.6e-01
cases:23.03%
controls:13.29%
cases:17.11%
controls:5.00%
cases:19.08%
controls:0.66%
—
—
cases:11.92%
controls:0.79%
cases:14.29%
controls:4.58%
cases:15.94%
controls:11.70%
35
202
117
1318
26
76
126
1444
29
10
123
1510
—
18
12
133
1508
21
69
126
1438
22
170
116
1283
General Practice
1 [38004446]
5.9e-01
1.5e+00
2.4e+00
1.0e+50
2.7e+00
1.2e+00
8.8e-01
cases:13.16%
controls:7.76%
cases:17.11%
controls:4.41%
cases:7.24%
controls:0.72%
cases:7.24%
controls:0.00%
cases:8.61%
controls:0.66%
cases:12.24%
controls:3.98%
cases:25.36%
controls:12.32%
20
118
132
1402
26
67
126
1453
11
11
141
1509
11
0
141
1520
13
10
138
1510
18
60
129
1447
35
179
103
1274
Intravenous general anesthesia
WX404 [2001310807]
1.8e+00
2.2e+00
1.0e+50
—
—
2.4e+00
1.9e+00
cases:4.61%
controls:0.79%
cases:5.26%
controls:0.59%
cases:3.29%
controls:0.00%
—
—
—
—
cases:4.76%
controls:0.46%
cases:10.14%
controls:1.58%
7
12
145
1508
8
9
144
1511
5
0
147
1520
—
—
7
7
140
1500
14
23
124
1430
More than one and less than three hours
ZXE10 [2001311401]
1.5e+00
3.0e+00
1.0e+50
1.0e+50
—
1.7e+00
1.9e+00
cases:13.82%
controls:3.42%
cases:17.76%
controls:1.05%
cases:12.50%
controls:0.00%
cases:3.29%
controls:0.00%
—
—
cases:8.16%
controls:1.59%
cases:20.29%
controls:3.79%
21
52
131
1468
27
16
125
1504
19
0
133
1520
5
0
147
1520
—
12
24
135
1483
28
55
110
1398
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
1.1e+00
1.4e+00
2.8e+00
—
2.2e+00
1.4e+00
1.1e+00
cases:15.13%
controls:5.66%
cases:9.21%
controls:2.37%
cases:5.26%
controls:0.33%
—
—
cases:3.31%
controls:0.39%
cases:10.20%
controls:2.65%
cases:17.39%
controls:6.26%
23
86
129
1434
14
36
138
1484
8
5
144
1515
—
5
6
146
1514
15
40
132
1467
24
91
114
1362
Pharmacy visit
OMOP4822462 [581458]
9.7e-01
1.3e+00
1.4e+00
2.7e+00
1.3e+00
1.1e+00
1.4e+00
cases:96.71%
controls:91.78%
cases:92.76%
controls:77.83%
cases:69.74%
controls:36.91%
cases:19.74%
controls:1.64%
cases:68.87%
controls:38.68%
cases:91.84%
controls:78.83%
cases:98.55%
controls:94.43%
147
1395
5
125
141
1183
11
337
106
561
46
959
30
25
122
1495
104
588
47
932
135
1188
12
319
136
1372
2
81
Internal Medicine
11 [38004456]
6.2e-01
1.4e+00
1.8e+00
—
1.6e+00
1.4e+00
8.7e-01
cases:35.53%
controls:22.89%
cases:29.61%
controls:9.01%
cases:11.18%
controls:2.11%
—
—
cases:8.61%
controls:1.91%
cases:30.61%
controls:9.62%
cases:42.03%
controls:23.33%
54
348
98
1172
45
137
107
1383
17
32
135
1488
—
13
29
138
1491
45
145
102
1362
58
339
80
1114
Medical Oncology
90 [38004507]
9.4e-01
2.0e+00
2.2e+00
—
2.2e+00
2.1e+00
1.3e+00
cases:3.95%
controls:1.58%
cases:7.24%
controls:1.05%
cases:4.61%
controls:0.53%
—
—
cases:3.31%
controls:0.39%
cases:7.48%
controls:1.00%
cases:9.42%
controls:2.75%
6
24
146
1496
11
16
141
1504
7
8
145
1512
—
5
6
146
1514
11
15
136
1492
13
40
125
1413
Upper gastrointestinal surgery
106 [44777669]
6.8e-01
2.4e+00
—
—
2.3e+00
1.6e+00
1.1e+00
cases:9.21%
controls:4.87%
cases:14.47%
controls:1.58%
—
—
—
—
cases:3.97%
controls:0.39%
cases:9.52%
controls:2.12%
cases:20.29%
controls:7.98%
14
74
138
1446
22
24
130
1496
—
—
6
6
145
1514
14
32
133
1475
28
116
110
1337
Gastroenterology
10 [38004455]
1.5e+00
2.0e+00
—
—
—
2.3e+00
1.4e+00
cases:7.89%
controls:1.91%
cases:7.24%
controls:1.05%
—
—
—
—
—
—
cases:8.16%
controls:0.86%
cases:13.04%
controls:3.65%
12
29
140
1491
11
16
141
1504
—
—
—
12
13
135
1494
18
53
120
1400
Scheduled procedure
ZXD10 [2001311387]
9.8e-01
2.5e+00
—
—
—
1.8e+00
1.5e+00
cases:15.13%
controls:6.25%
cases:16.45%
controls:1.51%
—
—
—
—
—
—
cases:10.20%
controls:1.79%
cases:20.29%
controls:5.23%
23
95
129
1425
25
23
127
1497
—
—
—
15
27
132
1480
28
76
110
1377
Plastic And Reconstructive Surgery
24 [38004467]
1.4e+00
2.8e+00
—
—
—
2.2e+00
1.6e+00
cases:4.61%
controls:1.12%
cases:7.89%
controls:0.53%
—
—
—
—
—
—
cases:6.80%
controls:0.80%
cases:7.97%
controls:1.72%
7
17
145
1503
12
8
140
1512
—
—
—
10
12
137
1495
11
25
127
1428
Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
Y83 [45552036]
1.9e+00
—
1.0e+50
1.0e+50
1.0e+50
3.7e+00
2.5e+00
cases:3.29%
controls:0.53%
—
—
cases:13.16%
controls:0.00%
cases:5.92%
controls:0.00%
cases:13.91%
controls:0.00%
cases:11.56%
controls:0.33%
cases:8.70%
controls:0.76%
5
8
147
1512
—
20
0
132
1520
9
0
143
1520
21
0
130
1520
17
5
130
1502
12
11
126
1442
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
8.6e-01
1.9e+00
1.0e+50
—
—
2.4e+00
1.6e+00
cases:3.95%
controls:1.71%
cases:4.61%
controls:0.72%
cases:3.95%
controls:0.00%
—
—
—
—
cases:4.08%
controls:0.40%
cases:7.97%
controls:1.72%
6
26
146
1494
7
11
145
1509
6
0
146
1520
—
—
6
6
141
1501
11
25
127
1428
Physical Medicine And Rehabilitation
25 [38004468]
1.4e+00
1.5e+00
—
—
—
1.6e+00
1.2e+00
cases:12.50%
controls:3.49%
cases:6.58%
controls:1.51%
—
—
—
—
—
—
cases:8.84%
controls:1.92%
cases:15.94%
controls:5.44%
19
53
133
1467
10
23
142
1497
—
—
—
13
29
134
1478
22
79
116
1374
Treatment plan or consultation
WZC00 [2001310885]
—
2.2e+00
—
—
—
1.9e+00
1.4e+00
—
—
cases:4.61%
controls:0.53%
—
—
—
—
—
—
cases:4.76%
controls:0.73%
cases:10.14%
controls:2.82%
—
7
8
145
1512
—
—
—
7
11
140
1496
14
41
124
1412
Thorax X-ray examination
GD1AA [2001303617]
1.9e-01
2.0e+00
—
1.0e+50
—
2.3e+00
1.1e+00
cases:3.95%
controls:3.29%
cases:7.89%
controls:1.12%
—
—
cases:3.29%
controls:0.00%
—
—
cases:8.16%
controls:0.86%
cases:16.67%
controls:6.54%
6
50
146
1470
12
17
140
1503
—
5
0
147
1520
—
12
13
135
1494
23
95
115
1358
Infiltration anesthesia
WX110 [2001310767]
1.0e+00
1.8e+00
2.5e+00
—
—
6.8e-01
6.1e-01
cases:11.18%
controls:4.34%
cases:11.18%
controls:2.04%
cases:4.61%
controls:0.39%
—
—
—
—
cases:6.12%
controls:3.19%
cases:21.74%
controls:13.08%
17
66
135
1454
17
31
135
1489
7
6
145
1514
—
—
9
48
138
1459
30
190
108
1263
Urgent procedure
ZXD05 [2001311386]
8.1e-01
2.4e+00
—
1.0e+50
—
1.8e+00
1.1e+00
cases:6.58%
controls:3.03%
cases:11.84%
controls:1.25%
—
—
cases:7.89%
controls:0.00%
—
—
cases:4.76%
controls:0.80%
cases:10.87%
controls:4.06%
10
46
142
1474
18
19
134
1501
—
12
0
140
1520
—
7
12
140
1495
15
59
123
1394
Otolaryngology
4 [38004449]
7.0e-01
1.1e+00
2.5e+00
1.0e+50
—
1.3e+00
6.2e-01
cases:15.13%
controls:8.16%
cases:8.55%
controls:2.96%
cases:3.95%
controls:0.33%
cases:3.95%
controls:0.00%
—
—
cases:10.88%
controls:3.12%
cases:17.39%
controls:10.19%
23
124
129
1396
13
45
139
1475
6
5
146
1515
6
0
146
1520
—
16
47
131
1460
24
148
114
1305
More than three and less than five hours
ZXE20 [2001311408]
1.0e+00
2.5e+00
1.0e+50
—
—
2.5e+00
1.6e+00
cases:3.29%
controls:1.18%
cases:7.89%
controls:0.72%
cases:5.26%
controls:0.00%
—
—
—
—
cases:5.44%
controls:0.46%
cases:4.35%
controls:0.89%
5
18
147
1502
12
11
140
1509
8
0
144
1520
—
—
8
7
139
1500
6
13
132
1440
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
7.8e-01
8.5e-01
1.3e+00
—
2.0e+00
1.2e+00
9.0e-01
cases:25.00%
controls:13.29%
cases:14.47%
controls:6.78%
cases:5.26%
controls:1.51%
—
—
cases:10.60%
controls:1.58%
cases:20.41%
controls:7.50%
cases:47.83%
controls:27.12%
38
202
114
1318
22
103
130
1417
8
23
144
1497
—
16
24
135
1496
30
113
117
1394
66
394
72
1059
Infection following a procedure, not elsewhere classified
T81.4 [45575538]
2.3e+00
—
—
1.0e+50
—
—
2.3e+00
cases:4.61%
controls:0.46%
—
—
—
—
cases:12.50%
controls:0.00%
—
—
—
—
cases:7.97%
controls:0.89%
7
7
145
1513
—
—
19
0
133
1520
—
—
11
13
127
1440
Exposure to unspecified factor
X59 [45756412]
1.0e+00
2.5e+00
—
—
—
2.0e+00
9.5e-01
cases:3.29%
controls:1.18%
cases:5.92%
controls:0.53%
—
—
—
—
—
—
cases:4.76%
controls:0.66%
cases:4.35%
controls:1.72%
5
18
147
1502
9
8
143
1512
—
—
—
7
10
140
1497
6
25
132
1428
General anesthesia, balanced
WX408 [2001310808]
1.3e+00
2.6e+00
1.0e+50
1.0e+50
—
1.6e+00
1.8e+00
cases:6.58%
controls:1.84%
cases:11.18%
controls:0.92%
cases:8.55%
controls:0.00%
cases:3.29%
controls:0.00%
—
—
cases:4.08%
controls:0.86%
cases:10.14%
controls:1.86%
10
28
142
1492
17
14
135
1506
13
0
139
1520
5
0
147
1520
—
6
13
141
1494
14
27
124
1426
Essential (primary) hypertension
I10 [45591453]
2.9e-01
1.3e+00
2.2e+00
—
1.6e+00
8.0e-01
7.4e-01
cases:13.16%
controls:10.20%
cases:15.13%
controls:4.47%
cases:5.92%
controls:0.66%
—
—
cases:4.64%
controls:0.99%
cases:11.56%
controls:5.57%
cases:28.99%
controls:16.24%
20
155
132
1365
23
68
129
1452
9
10
143
1510
—
7
15
144
1505
17
84
130
1423
40
236
98
1217
Other seropositive rheumatoid arthritis
M05.8 [45538634]
1.8e+00
2.5e+00
—
—
—
2.0e+00
1.1e+00
cases:4.61%
controls:0.79%
cases:4.61%
controls:0.39%
—
—
—
—
—
—
cases:4.08%
controls:0.60%
cases:3.62%
controls:1.24%
7
12
145
1508
7
6
145
1514
—
—
—
6
9
141
1498
5
18
133
1435
Left side
ZXA05 [2001311347]
1.1e+00
2.8e+00
—
—
—
2.0e+00
1.4e+00
cases:6.58%
controls:2.24%
cases:7.89%
controls:0.53%
—
—
—
—
—
—
cases:4.08%
controls:0.60%
cases:13.04%
controls:3.44%
10
34
142
1486
12
8
140
1512
—
—
—
6
9
141
1498
18
50
120
1403
Psychiatry
26 [38004469]
1.2e+00
9.2e-01
1.7e+00
—
1.8e+00
1.0e+00
1.1e+00
cases:10.53%
controls:3.29%
cases:5.92%
controls:2.43%
cases:4.61%
controls:0.86%
—
—
cases:4.64%
controls:0.79%
cases:6.80%
controls:2.59%
cases:13.04%
controls:4.61%
16
50
136
1470
9
37
143
1483
7
13
145
1507
—
7
12
144
1508
10
39
137
1468
18
67
120
1386
Right side
ZXA00 [2001311346]
1.0e+00
2.8e+00
—
—
—
—
1.3e+00
cases:6.58%
controls:2.50%
cases:7.89%
controls:0.53%
—
—
—
—
—
—
—
—
cases:13.77%
controls:4.06%
10
38
142
1482
12
8
140
1512
—
—
—
—
19
59
119
1394
zopiclone; oral
N05CF01 [21604654]
8.7e-01
1.1e+00
1.6e+00
—
—
1.0e+00
1.0e+00
cases:14.47%
controls:6.64%
cases:11.18%
controls:3.88%
cases:4.61%
controls:0.92%
—
—
—
—
cases:11.56%
controls:4.45%
cases:18.12%
controls:7.23%
22
101
130
1419
17
59
135
1461
7
14
145
1506
—
—
17
67
130
1440
25
105
113
1348
codeine and paracetamol
N02AJ06 [1123647]
5.4e-01
1.4e+00
2.7e+00
—
—
4.7e-01
3.2e-01
cases:9.87%
controls:5.99%
cases:11.18%
controls:3.16%
cases:4.61%
controls:0.33%
—
—
—
—
cases:6.12%
controls:3.92%
cases:15.94%
controls:12.11%
15
91
137
1429
17
48
135
1472
7
5
145
1515
—
—
9
59
138
1448
22
176
116
1277
furosemide; oral, parenteral
C03CA01 [21601518]
6.8e-01
1.2e+00
—
—
—
1.4e+00
1.2e+00
cases:7.89%
controls:4.14%
cases:11.18%
controls:3.62%
—
—
—
—
—
—
cases:12.93%
controls:3.65%
cases:16.67%
controls:5.92%
12
63
140
1457
17
55
135
1465
—
—
—
19
55
128
1452
23
86
115
1367
Coloscopy
UJF32 [2001305029]
8.6e-01
1.8e+00
—
—
—
1.8e+00
8.7e-01
cases:6.58%
controls:2.89%
cases:5.92%
controls:0.99%
—
—
—
—
—
—
cases:4.76%
controls:0.80%
cases:8.70%
controls:3.85%
10
44
142
1476
9
15
143
1505
—
—
—
7
12
140
1495
12
56
126
1397
Cardiology
6 [38004451]
2.8e-01
1.5e+00
—
1.0e+50
1.8e+00
1.3e+00
8.3e-01
cases:6.58%
controls:5.07%
cases:11.84%
controls:2.89%
—
—
cases:3.29%
controls:0.00%
cases:3.97%
controls:0.66%
cases:9.52%
controls:2.79%
cases:17.39%
controls:8.40%
10
77
142
1443
18
44
134
1476
—
5
0
147
1520
6
10
145
1510
14
42
133
1465
24
122
114
1331
One hour or less
ZXE00 [2001311394]
7.6e-01
2.7e+00
1.0e+50
1.0e+50
—
—
9.2e-01
cases:9.21%
controls:4.54%
cases:12.50%
controls:0.99%
cases:7.24%
controls:0.00%
cases:3.95%
controls:0.00%
—
—
—
—
cases:13.77%
controls:5.99%
14
69
138
1451
19
15
133
1505
11
0
141
1520
6
0
146
1520
—
—
19
87
119
1366
Atherosclerosis of arteries of extremities
I70.2 [45538421]
9.4e-01
2.1e+00
—
—
—
2.0e+00
1.5e+00
cases:3.29%
controls:1.32%
cases:3.29%
controls:0.39%
—
—
—
—
—
—
cases:4.76%
controls:0.66%
cases:7.97%
controls:1.93%
5
20
147
1500
5
6
147
1514
—
—
—
7
10
140
1497
11
28
127
1425
ibuprofen
R02AX02 [1588667]
8.0e-01
7.2e-01
1.8e+00
—
1.3e+00
6.3e-01
4.6e-01
cases:44.74%
controls:26.64%
cases:21.05%
controls:11.45%
cases:8.55%
controls:1.45%
—
—
cases:4.64%
controls:1.32%
cases:19.05%
controls:11.15%
cases:42.75%
controls:32.14%
68
405
84
1115
32
174
120
1346
13
22
139
1498
—
7
20
144
1500
28
168
119
1339
59
467
79
986
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
8.0e-01
7.2e-01
1.8e+00
—
1.3e+00
6.3e-01
4.6e-01
cases:44.74%
controls:26.64%
cases:21.05%
controls:11.45%
cases:8.55%
controls:1.45%
—
—
cases:4.64%
controls:1.32%
cases:19.05%
controls:11.15%
cases:42.75%
controls:32.14%
68
405
84
1115
32
174
120
1346
13
22
139
1498
—
7
20
144
1500
28
168
119
1339
59
467
79
986
Atherosclerotic heart disease
I25.1 [45596196]
-8.0e-02
1.7e+00
—
—
2.2e+00
1.6e+00
3.6e-01
cases:3.29%
controls:3.55%
cases:7.24%
controls:1.38%
—
—
—
—
cases:3.31%
controls:0.39%
cases:6.12%
controls:1.33%
cases:7.25%
controls:5.16%
5
54
147
1466
11
21
141
1499
—
—
5
6
146
1514
9
20
138
1487
10
75
128
1378
Physiotherapy
R4110 [2001310233]
1.2e+00
2.0e+00
—
1.0e+50
—
1.4e+00
1.2e+00
cases:7.24%
controls:2.37%
cases:8.55%
controls:1.25%
—
—
cases:3.29%
controls:0.00%
—
—
cases:4.08%
controls:1.06%
cases:9.42%
controls:3.10%
11
36
141
1484
13
19
139
1501
—
5
0
147
1520
—
6
16
141
1491
13
45
125
1408
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
8.4e-01
3.2e+00
1.0e+50
—
—
—
1.1e+00
cases:3.29%
controls:1.45%
cases:7.24%
controls:0.33%
cases:3.29%
controls:0.00%
—
—
—
—
—
—
cases:4.35%
controls:1.45%
5
22
147
1498
11
5
141
1515
5
0
147
1520
—
—
—
6
21
132
1432
Infectious Disease
44 [38004484]
—
—
—
1.0e+50
—
3.0e+00
1.6e+00
—
—
—
—
—
—
cases:3.29%
controls:0.00%
—
—
cases:7.48%
controls:0.40%
cases:5.07%
controls:1.10%
—
—
—
5
0
147
1520
—
11
6
136
1501
7
16
131
1437
Insertion of central venous catheter through external or internal jugular vein
TPH15 [2001309600]
-1.0e+50
2.9e+00
—
—
—
—
2.2e+00
cases:0.00%
controls:0.33%
cases:6.58%
controls:0.39%
—
—
—
—
—
—
—
—
cases:3.62%
controls:0.41%
0
5
152
1515
10
6
142
1514
—
—
—
—
5
6
133
1447
Lumbar spine X-ray examination without contrast
NA3AA [2001307026]
—
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.52%
controls:0.48%
—
—
—
—
—
—
9
7
129
1446
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
7.7e-02
1.8e+00
—
—
—
1.1e+00
8.5e-01
cases:6.58%
controls:6.12%
cases:7.89%
controls:1.38%
—
—
—
—
—
—
cases:4.76%
controls:1.59%
cases:16.67%
controls:7.85%
10
93
142
1427
12
21
140
1499
—
—
—
7
24
140
1483
23
114
115
1339
pantoprazole; oral, parenteral
A02BC02 [21600097]
8.5e-01
9.7e-01
1.2e+00
—
1.2e+00
9.9e-01
7.7e-01
cases:15.13%
controls:7.11%
cases:10.53%
controls:4.28%
cases:3.29%
controls:0.99%
—
—
cases:3.97%
controls:1.25%
cases:12.93%
controls:5.24%
cases:28.99%
controls:15.83%
23
108
129
1412
16
65
136
1455
5
15
147
1505
—
6
19
145
1501
19
79
128
1428
40
230
98
1223
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
8.3e-01
1.2e+00
—
—
—
1.5e+00
1.1e+00
cases:10.53%
controls:4.87%
cases:7.24%
controls:2.30%
—
—
—
—
—
—
cases:8.84%
controls:2.19%
cases:15.22%
controls:5.57%
16
74
136
1446
11
35
141
1485
—
—
—
13
33
134
1474
21
81
117
1372
Diarrhoea
D11 [2002000310]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.35%
controls:0.34%
—
—
—
—
—
—
6
5
132
1448
Measurement of bone density from two or more locations with X-ray
NK6QA [2001308500]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.07%
controls:0.41%
—
—
—
—
—
—
7
6
131
1447
Care involving use of other rehabilitation procedures
Z50.8 [45556842]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.80%
controls:0.48%
—
—
—
—
—
—
8
7
130
1446
Respiratory and circulatory monitoring
WX700 [2001310817]
—
1.9e+00
—
—
—
2.0e+00
2.5e+00
—
—
cases:3.95%
controls:0.59%
—
—
—
—
—
—
cases:3.40%
controls:0.46%
cases:7.25%
controls:0.62%
—
6
9
146
1511
—
—
—
5
7
142
1500
10
9
128
1444
Anesthesiology Critical Care Medicine
OMOP4821991 [45756751]
2.5e+00
—
—
—
—
—
1.6e+00
cases:4.61%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
cases:3.62%
controls:0.76%
7
6
145
1514
—
—
—
—
—
5
11
133
1442
Other diagnostic examination of periferal vessel
XPX99 [2001309755]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.80%
controls:0.55%
—
—
—
—
—
—
8
8
130
1445
tamoxifen; oral
L02BA01 [21603831]
-1.0e+50
—
—
—
—
—
2.4e+00
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
cases:4.35%
controls:0.41%
0
5
152
1515
—
—
—
—
—
6
6
132
1447
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
LC2BE [2001306544]
1.0e+00
2.4e+00
—
1.0e+50
—
1.8e+00
1.1e+00
cases:6.58%
controls:2.50%
cases:6.58%
controls:0.66%
—
—
cases:4.61%
controls:0.00%
—
—
cases:4.08%
controls:0.66%
cases:6.52%
controls:2.20%
10
38
142
1482
10
10
142
1510
—
7
0
145
1520
—
6
10
141
1497
9
32
129
1421
Laceration/cut
S18 [2002000983]
—
2.3e+00
—
—
—
1.6e+00
8.7e-01
—
—
cases:5.26%
controls:0.53%
—
—
—
—
—
—
cases:4.76%
controls:1.00%
cases:11.59%
controls:5.23%
—
8
8
144
1512
—
—
—
7
15
140
1492
16
76
122
1377
Pain in limb
M79.6 [45587063]
6.3e-01
2.3e+00
—
—
—
1.1e+00
9.4e-01
cases:3.29%
controls:1.78%
cases:3.95%
controls:0.39%
—
—
—
—
—
—
cases:3.40%
controls:1.13%
cases:7.25%
controls:2.96%
5
27
147
1493
6
6
146
1514
—
—
—
5
17
142
1490
10
43
128
1410
clindamycin; oral, parenteral
J01FF01 [21602985]
1.0e+00
1.5e+00
—
—
—
2.3e+00
9.1e-01
cases:8.55%
controls:3.22%
cases:5.26%
controls:1.18%
—
—
—
—
—
—
cases:6.80%
controls:0.73%
cases:7.97%
controls:3.37%
13
49
139
1471
8
18
144
1502
—
—
—
10
11
137
1496
11
49
127
1404
Ultrasound examination of mammary glands
HA1AE [2001303886]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.07%
controls:0.55%
—
—
—
—
—
—
7
8
131
1445
FEV1 --post bronchodilation
20155-8 [3023550]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.35%
controls:0.48%
—
—
—
—
—
—
6
7
132
1446
FEV1/FVC
19926-5 [3011505]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.35%
controls:0.48%
—
—
—
—
—
—
6
7
132
1446
FEV1
20150-9 [3024653]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.35%
controls:0.48%
—
—
—
—
—
—
6
7
132
1446
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.35%
controls:0.48%
—
—
—
—
—
—
6
7
132
1446
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.35%
controls:0.48%
—
—
—
—
—
—
6
7
132
1446
FVC percent change Respiratory system
69982-7 [42868471]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.35%
controls:0.48%
—
—
—
—
—
—
6
7
132
1446
FEV1 percent change
69983-5 [42868472]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.35%
controls:0.48%
—
—
—
—
—
—
6
7
132
1446
FEV1/FVC --post bronchodilation
69970-2 [42868459]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.35%
controls:0.48%
—
—
—
—
—
—
6
7
132
1446
spironolactone; oral
C03DA01 [21601534]
—
—
—
—
—
2.2e+00
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:4.08%
controls:0.46%
cases:4.35%
controls:1.51%
—
—
—
—
—
6
7
141
1500
6
22
132
1431
Oral Surgery
19 [38004464]
1.5e+00
—
—
—
—
—
2.2e+00
cases:3.29%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
cases:5.80%
controls:0.69%
5
12
147
1508
—
—
—
—
—
8
10
130
1443
Physiotherapist
Z3226 [2001311560]
1.1e+00
2.1e+00
—
—
—
1.3e+00
1.1e+00
cases:7.24%
controls:2.50%
cases:9.87%
controls:1.32%
—
—
—
—
—
—
cases:4.76%
controls:1.33%
cases:6.52%
controls:2.20%
11
38
141
1482
15
20
137
1500
—
—
—
7
20
140
1487
9
32
129
1421
Observation for suspected disease or condition, unspecified
Z03.9 [45552062]
—
2.1e+00
—
—
—
2.1e+00
8.8e-01
—
—
cases:3.29%
controls:0.39%
—
—
—
—
—
—
cases:4.08%
controls:0.53%
cases:5.80%
controls:2.48%
—
5
6
147
1514
—
—
—
6
8
141
1499
8
36
130
1417
Abdominal ultrasound examination
JN3AE [2001305555]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.97%
controls:1.10%
—
—
—
—
—
—
11
16
127
1437
Dentistry
C5 [903277]
1.1e+00
2.0e+00
—
—
—
—
8.6e-01
cases:5.26%
controls:1.84%
cases:3.95%
controls:0.53%
—
—
—
—
—
—
—
—
cases:5.07%
controls:2.20%
8
28
144
1492
6
8
146
1512
—
—
—
—
7
32
131
1421
Written specialist consultation based on a referral from a dentist or a physician
WZC10 [2001310887]
2.0e+00
—
—
—
—
—
—
cases:3.95%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
6
8
146
1512
—
—
—
—
—
—
Lumbago with sciatica
M54.4 [45553205]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.52%
controls:0.89%
—
—
—
—
—
—
9
13
129
1440
Operative extraction of tooth
EBA10 [2001301925]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.07%
controls:0.69%
—
—
—
—
—
—
7
10
131
1443
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
3.4e-01
8.6e-01
—
—
—
2.0e+00
5.4e-01
cases:7.24%
controls:5.26%
cases:5.26%
controls:2.30%
—
—
—
—
—
—
cases:7.48%
controls:1.06%
cases:10.87%
controls:6.61%
11
80
141
1440
8
35
144
1485
—
—
—
11
16
136
1491
15
96
123
1357
Fall on same level from slipping, tripping and stumbling
W01 [45756243]
—
—
—
—
—
2.0e+00
1.0e+00
—
—
—
—
—
—
—
—
—
—
cases:6.12%
controls:0.86%
cases:9.42%
controls:3.58%
—
—
—
—
—
9
13
138
1494
13
52
125
1401
Examination and observation for other specified reasons
Z04.8 [45552063]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.52%
controls:0.96%
—
—
—
—
—
—
9
14
129
1439
Extensive abdominal CT
JN3BD [2001305556]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.52%
controls:0.96%
—
—
—
—
—
—
9
14
129
1439
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
6.5e-01
8.8e-01
1.5e+00
1.0e+50
1.9e+00
8.9e-01
2.4e-01
cases:3.95%
controls:2.11%
cases:6.58%
controls:2.83%
cases:4.61%
controls:1.05%
cases:3.29%
controls:0.00%
cases:5.30%
controls:0.79%
cases:8.84%
controls:3.85%
cases:21.01%
controls:17.34%
6
32
146
1488
10
43
142
1477
7
16
145
1504
5
0
147
1520
8
12
143
1508
13
58
134
1449
29
252
109
1201
Oncology Clinic/Center
261QX0200X [38004268]
9.4e-01
1.9e+00
—
—
—
—
3.7e-02
cases:7.24%
controls:2.96%
cases:7.24%
controls:1.12%
—
—
—
—
—
—
—
—
cases:4.35%
controls:4.20%
11
45
141
1475
11
17
141
1503
—
—
—
—
6
61
132
1392
celecoxib; oral
M01AH01 [21603992]
1.9e+00
—
—
—
—
—
8.6e-01
cases:7.24%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
cases:5.80%
controls:2.55%
11
18
141
1502
—
—
—
—
—
8
37
130
1416
celecoxib
L01XX33 [21603805]
1.9e+00
—
—
—
—
—
8.6e-01
cases:7.24%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
cases:5.80%
controls:2.55%
11
18
141
1502
—
—
—
—
—
8
37
130
1416
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
9.4e-01
1.6e+00
—
—
—
1.8e+00
7.0e-01
cases:4.61%
controls:1.84%
cases:4.61%
controls:0.92%
—
—
—
—
—
—
cases:4.76%
controls:0.80%
cases:5.80%
controls:2.96%
7
28
145
1492
7
14
145
1506
—
—
—
7
12
140
1495
8
43
130
1410
hydroxychloroquine; oral
P01BA02 [21604889]
1.4e+00
1.8e+00
—
—
-1.0e+50
1.6e+00
1.1e+00
cases:3.95%
controls:1.05%
cases:4.61%
controls:0.79%
—
—
—
—
cases:0.00%
controls:0.46%
cases:4.08%
controls:0.86%
cases:4.35%
controls:1.51%
6
16
146
1504
7
12
145
1508
—
—
0
7
151
1513
6
13
141
1494
6
22
132
1431
Lumbar and other intervertebral disc disorders with radiculopathy
M51.1 [45562747]
1.7e+00
—
—
—
—
—
1.5e+00
cases:5.92%
controls:1.12%
—
—
—
—
—
—
—
—
—
—
cases:4.35%
controls:0.96%
9
17
143
1503
—
—
—
—
—
6
14
132
1439
Other gastroenteritis and colitis of infectious and unspecified origin
A09 [45605189]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.52%
controls:1.24%
—
—
—
—
—
—
9
18
129
1435
Hand Surgery
40 [38004480]
9.4e-01
—
—
—
—
—
1.7e+00
cases:3.29%
controls:1.32%
—
—
—
—
—
—
—
—
—
—
cases:8.70%
controls:1.79%
5
20
147
1500
—
—
—
—
—
12
26
126
1427
Fever, unspecified
R50.9 [45582716]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.80%
controls:1.17%
—
—
—
—
—
—
8
17
130
1436
Urology
34 [38004474]
9.6e-01
8.2e-01
—
—
—
1.6e+00
7.5e-01
cases:7.24%
controls:2.89%
cases:3.95%
controls:1.78%
—
—
—
—
—
—
cases:7.48%
controls:1.59%
cases:9.42%
controls:4.68%
11
44
141
1476
6
27
146
1493
—
—
—
11
24
136
1483
13
68
125
1385
Depressive episode, unspecified
F32.9 [45571760]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.52%
controls:1.45%
—
—
—
—
—
—
9
21
129
1432
Acute maxillary sinusitis
J01.0 [45601112]
1.6e+00
—
—
—
—
—
—
cases:5.92%
controls:1.32%
—
—
—
—
—
—
—
—
—
—
—
—
9
20
143
1500
—
—
—
—
—
—
Vascular Surgery
77 [38004496]
—
—
1.0e+50
1.0e+50
—
2.2e+00
1.5e+00
—
—
—
—
cases:3.29%
controls:0.00%
cases:3.29%
controls:0.00%
—
—
cases:3.40%
controls:0.40%
cases:11.59%
controls:2.89%
—
—
5
0
147
1520
5
0
147
1520
—
5
6
142
1501
16
42
122
1411
Diabetes, insulin-treated
103 [2001600103]
4.3e-01
—
—
—
—
1.9e+00
1.5e+00
cases:3.29%
controls:2.17%
—
—
—
—
—
—
—
—
cases:3.40%
controls:0.53%
cases:7.97%
controls:1.93%
5
33
147
1487
—
—
—
—
5
8
142
1499
11
28
127
1425
pregabalin; oral
N02BF02 [955152]
1.0e+00
1.2e+00
—
—
—
1.6e+00
1.5e+00
cases:5.26%
controls:1.91%
cases:3.29%
controls:0.99%
—
—
—
—
—
—
cases:5.44%
controls:1.19%
cases:13.04%
controls:3.30%
8
29
144
1491
5
15
147
1505
—
—
—
8
18
139
1489
18
48
120
1405
Rheumatology
66 [38004491]
1.4e+00
1.6e+00
—
—
—
1.3e+00
7.8e-01
cases:6.58%
controls:1.64%
cases:3.95%
controls:0.79%
—
—
—
—
—
—
cases:4.08%
controls:1.13%
cases:5.80%
controls:2.75%
10
25
142
1495
6
12
146
1508
—
—
—
6
17
141
1490
8
40
130
1413
Foot/toe symptom/complaint
L17 [2002000641]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.97%
controls:2.06%
—
—
—
—
—
—
11
30
127
1423
Neurosurgery
14 [38004459]
1.5e+00
1.7e+00
—
—
—
—
1.4e+00
cases:5.26%
controls:1.18%
cases:3.29%
controls:0.59%
—
—
—
—
—
—
—
—
cases:7.25%
controls:1.93%
8
18
144
1502
5
9
147
1511
—
—
—
—
10
28
128
1425
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.25%
controls:1.93%
—
—
—
—
—
—
10
28
128
1425
enoxaparin; parenteral
B01AB05 [21600976]
1.3e+00
1.6e+00
—
—
—
—
1.4e+00
cases:5.92%
controls:1.64%
cases:3.95%
controls:0.79%
—
—
—
—
—
—
—
—
cases:13.77%
controls:3.92%
9
25
143
1495
6
12
146
1508
—
—
—
—
19
57
119
1396
isosorbide dinitrate; local oral, oral, sublingual, transdermal
C01DA08 [21600321]
5.4e-01
1.3e+00
-1.0e+50
—
—
1.2e+00
7.5e-01
cases:5.92%
controls:3.55%
cases:7.24%
controls:2.04%
cases:0.00%
controls:0.53%
—
—
—
—
cases:6.12%
controls:1.92%
cases:9.42%
controls:4.68%
9
54
143
1466
11
31
141
1489
0
8
152
1512
—
—
9
29
138
1478
13
68
125
1385
Supplier / Service Provider
OMOP5117446 [33004]
-2.2e+00
-2.8e-01
-1.0e+50
—
—
—
3.5e+00
cases:3.29%
controls:23.62%
cases:4.61%
controls:5.99%
cases:0.00%
controls:0.72%
—
—
—
—
—
—
cases:13.77%
controls:0.48%
5
359
147
1161
7
91
145
1429
0
11
152
1509
—
—
—
19
7
119
1446
ispaghula (psylla seeds); oral
A06AC01 [21600555]
8.7e-01
1.2e+00
—
—
—
1.4e+00
1.3e+00
cases:4.61%
controls:1.97%
cases:4.61%
controls:1.38%
—
—
—
—
—
—
cases:6.12%
controls:1.66%
cases:9.42%
controls:2.82%
7
30
145
1490
7
21
145
1499
—
—
—
9
25
138
1482
13
41
125
1412
Normoblasts [#/volume] in Blood
715-3 [3021589]
—
1.9e+00
—
—
—
—
1.2e+00
—
—
cases:3.95%
controls:0.59%
—
—
—
—
—
—
—
—
cases:9.42%
controls:2.89%
—
6
9
146
1511
—
—
—
—
13
42
125
1411
Low back pain
M54.5 [45553207]
1.3e+00
—
—
—
—
—
1.2e+00
cases:5.26%
controls:1.51%
—
—
—
—
—
—
—
—
—
—
cases:8.70%
controls:2.68%
8
23
144
1497
—
—
—
—
—
12
39
126
1414
Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]
1.0e+00
—
—
—
—
—
1.2e+00
cases:4.61%
controls:1.71%
—
—
—
—
—
—
—
—
—
—
cases:10.87%
controls:3.44%
7
26
145
1494
—
—
—
—
—
15
50
123
1403
metronidazole; oral, rectal
P01AB01 [21604857]
1.2e+00
1.4e+00
—
1.0e+50
—
1.1e+00
8.3e-01
cases:15.13%
controls:5.07%
cases:5.26%
controls:1.32%
—
—
cases:3.29%
controls:0.00%
—
—
cases:4.76%
controls:1.59%
cases:12.32%
controls:5.78%
23
77
129
1443
8
20
144
1500
—
5
0
147
1520
—
7
24
140
1483
17
84
121
1369
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
9.6e-01
—
—
—
—
1.6e+00
1.1e+00
cases:7.24%
controls:2.89%
—
—
—
—
—
—
—
—
cases:4.08%
controls:0.86%
cases:10.87%
controls:3.99%
11
44
141
1476
—
—
—
—
6
13
141
1494
15
58
123
1395
mirtazapine; oral
N06AX11 [21604740]
4.8e-01
—
-1.0e+50
—
—
6.7e-01
1.1e+00
cases:5.92%
controls:3.75%
—
—
cases:0.00%
controls:0.66%
—
—
—
—
cases:4.08%
controls:2.12%
cases:13.04%
controls:4.89%
9
57
143
1463
—
0
10
152
1510
—
—
6
32
141
1475
18
71
120
1382
Extended examination of mouth
SAA03 [2001310276]
7.7e-01
—
—
—
—
1.1e+00
1.0e+00
cases:5.26%
controls:2.50%
—
—
—
—
—
—
—
—
cases:4.76%
controls:1.59%
cases:15.22%
controls:6.06%
8
38
144
1482
—
—
—
—
7
24
140
1483
21
88
117
1365
Intraoral radiographic dental examination
EB1AA [2001301903]
—
9.8e-01
—
—
—
9.0e-01
1.0e+00
—
—
cases:3.95%
controls:1.51%
—
—
—
—
—
—
cases:4.76%
controls:1.99%
cases:22.46%
controls:9.43%
—
6
23
146
1497
—
—
—
7
30
140
1477
31
137
107
1316
omeprazole; oral, parenteral
A02BC01 [21600096]
1.0e+00
8.1e-01
-1.0e+50
—
—
—
3.1e-01
cases:11.18%
controls:4.41%
cases:4.61%
controls:2.11%
cases:0.00%
controls:0.66%
—
—
—
—
—
—
cases:5.07%
controls:3.79%
17
67
135
1453
7
32
145
1488
0
10
152
1510
—
—
—
7
55
131
1398
Pulmonary Disease
29 [38004472]
1.8e-01
6.2e-01
—
—
—
8.0e-01
9.6e-01
cases:7.24%
controls:6.12%
cases:5.26%
controls:2.89%
—
—
—
—
—
—
cases:6.12%
controls:2.85%
cases:18.12%
controls:7.78%
11
93
141
1427
8
44
144
1476
—
—
—
9
43
138
1464
25
113
113
1340
Type 2 diabetes mellitus, without complications
E11.9 [45561952]
—
9.2e-01
—
—
—
1.0e+00
9.2e-01
—
—
cases:5.26%
controls:2.17%
—
—
—
—
—
—
cases:6.80%
controls:2.52%
cases:13.77%
controls:5.99%
—
8
33
144
1487
—
—
—
10
38
137
1469
19
87
119
1366
fluconazole; oral, parenteral
J02AC01 [21603080]
9.2e-01
1.1e+00
—
—
—
1.3e+00
8.5e-01
cases:16.45%
controls:7.30%
cases:7.89%
controls:2.70%
—
—
—
—
—
—
cases:7.48%
controls:2.26%
cases:15.94%
controls:7.50%
25
111
127
1409
12
41
140
1479
—
—
—
11
34
136
1473
22
109
116
1344
calcium (different salts in combination); oral
A12AA20 [21600872]
7.7e-01
8.6e-01
—
—
1.6e+00
9.2e-01
9.0e-01
cases:8.55%
controls:4.14%
cases:8.55%
controls:3.82%
—
—
—
—
cases:3.97%
controls:0.86%
cases:10.20%
controls:4.31%
cases:17.39%
controls:7.91%
13
63
139
1457
13
58
139
1462
—
—
6
13
145
1507
15
65
132
1442
24
115
114
1338
Telehealth
OMOP5556618 [722455]
5.1e-01
4.9e-01
1.6e+00
—
—
8.8e-01
5.3e-01
cases:10.53%
controls:6.58%
cases:9.21%
controls:5.86%
cases:4.61%
controls:0.99%
—
—
—
—
cases:14.29%
controls:6.44%
cases:28.26%
controls:18.79%
16
100
136
1420
14
89
138
1431
7
15
145
1505
—
—
21
97
126
1410
39
273
99
1180
ketoprofen; oral, parenteral, rectal
M01AE03 [21603969]
8.8e-01
1.2e+00
—
—
—
6.2e-01
3.9e-01
cases:15.79%
controls:7.24%
cases:5.26%
controls:1.71%
—
—
—
—
—
—
cases:3.40%
controls:1.86%
cases:7.25%
controls:5.02%
24
110
128
1410
8
26
144
1494
—
—
—
5
28
142
1479
10
73
128
1380
prednisolone; oral, parenteral
H02AB06 [21602734]
8.6e-01
6.3e-01
—
—
1.9e+00
6.2e-01
6.4e-01
cases:14.47%
controls:6.71%
cases:6.58%
controls:3.62%
—
—
—
—
cases:3.97%
controls:0.59%
cases:6.80%
controls:3.78%
cases:16.67%
controls:9.57%
22
102
130
1418
10
55
142
1465
—
—
6
9
145
1511
10
57
137
1450
23
139
115
1314
prednisolone
A07EA01 [21600653]
8.6e-01
6.3e-01
—
—
1.9e+00
7.2e-01
6.3e-01
cases:14.47%
controls:6.71%
cases:6.58%
controls:3.62%
—
—
—
—
cases:3.97%
controls:0.59%
cases:7.48%
controls:3.78%
cases:16.67%
controls:9.64%
22
102
130
1418
10
55
142
1465
—
—
6
9
145
1511
11
57
136
1450
23
140
115
1313
naproxen; oral, rectal
M01AE02 [21603968]
8.2e-01
1.1e+00
—
—
—
6.3e-01
1.2e-02
cases:18.42%
controls:9.08%
cases:6.58%
controls:2.24%
—
—
—
—
—
—
cases:4.76%
controls:2.59%
cases:8.70%
controls:8.60%
28
138
124
1382
10
34
142
1486
—
—
—
7
39
140
1468
12
125
126
1328
naproxcinod
M01AE18 [40254094]
8.2e-01
1.1e+00
—
—
—
6.3e-01
1.2e-02
cases:18.42%
controls:9.08%
cases:6.58%
controls:2.24%
—
—
—
—
—
—
cases:4.76%
controls:2.59%
cases:8.70%
controls:8.60%
28
138
124
1382
10
34
142
1486
—
—
—
7
39
140
1468
12
125
126
1328
diclofenac; oral, parenteral, rectal
M01AB05 [21603945]
6.9e-01
5.3e-01
-1.0e+50
—
—
8.9e-01
3.0e-01
cases:24.34%
controls:13.88%
cases:7.24%
controls:4.41%
cases:0.00%
controls:0.92%
—
—
—
—
cases:11.56%
controls:5.11%
cases:18.12%
controls:14.04%
37
211
115
1309
11
67
141
1453
0
14
152
1506
—
—
17
77
130
1430
25
204
113
1249
Case Management Agency
251B00000X [38004193]
5.8e-01
4.6e-01
6.1e-01
—
7.1e-01
6.1e-01
2.0e-01
cases:40.79%
controls:27.83%
cases:30.92%
controls:21.97%
cases:11.84%
controls:6.78%
—
—
cases:13.91%
controls:7.37%
cases:37.41%
controls:24.49%
cases:57.97%
controls:53.06%
62
423
90
1097
47
334
105
1186
18
103
134
1417
—
21
112
130
1408
55
369
92
1138
80
771
58
682
fusidic acid; ointment
D06AX01 [21602062]
—
—
—
—
—
—
8.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.07%
controls:2.27%
—
—
—
—
—
—
7
33
131
1420
ezetimibe; oral
C10AX09 [21601896]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
0
5
152
1515
—
—
—
—
Angiography of heart and/or coronary arteries
FN1AC [2001302996]
—
1.6e+00
—
—
—
—
—
—
—
cases:4.61%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
7
14
145
1506
—
—
—
—
—
Pain localized to other parts of lower abdomen
R10.3 [45534426]
7.9e-01
—
—
—
—
—
5.4e-01
cases:3.29%
controls:1.51%
—
—
—
—
—
—
—
—
—
—
cases:3.62%
controls:2.13%
5
23
147
1497
—
—
—
—
—
5
31
133
1422
ethylmorphine; oral
R05DA01 [21603397]
—
—
—
—
—
—
4.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.62%
controls:2.34%
—
—
—
—
—
—
5
34
133
1419
Hearing loss, unspecified
H91.9 [45547996]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
152
1515
—
—
—
—
—
—
Extensive CT of neck arteries
PA6BD [2001308697]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
6
138
1447
intermediate-acting sulfonamides - combinations
J01EC20 [21602948]
2.0e-01
-1.0e+50
—
—
—
—
8.7e-01
cases:4.61%
controls:3.82%
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
—
cases:4.35%
controls:1.86%
7
58
145
1462
0
11
152
1509
—
—
—
—
6
27
132
1426
natamycin
D01AA02 [21601912]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
152
1513
—
—
—
—
—
—
methylprednisolone; oral, parenteral
H02AB04 [21602732]
5.0e-01
—
—
—
—
—
8.4e-01
cases:3.95%
controls:2.43%
—
—
—
—
—
—
—
—
—
—
cases:4.35%
controls:1.93%
6
37
146
1483
—
—
—
—
—
6
28
132
1425
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
0
10
138
1443
Umbilical hernia without obstruction or gangrene
K42.9 [45591589]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
152
1515
—
—
—
—
—
—
sulfadiazine and trimethoprim
J01EE02 [21602962]
4.8e-01
—
—
—
—
1.4e+00
—
cases:5.92%
controls:3.75%
—
—
—
—
—
—
—
—
cases:4.08%
controls:1.00%
—
—
9
57
143
1463
—
—
—
—
6
15
141
1492
—
Senile macular degeneration (atrophic)(exudative)
H35.31 [2000502315]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
0
10
138
1443
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
9
138
1444
Benign paroxysmal vertigo
H81.1 [45572061]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
0
7
152
1513
—
—
—
—
—
0
9
138
1444
norfloxacin; oral
J01MA06 [21603013]
6.3e-01
—
—
—
—
—
5.1e-01
cases:3.29%
controls:1.78%
—
—
—
—
—
—
—
—
—
—
cases:3.62%
controls:2.20%
5
27
147
1493
—
—
—
—
—
5
32
133
1421
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
—
—
—
—
—
—
5.3e-02
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.62%
controls:3.44%
—
—
—
—
—
—
5
50
133
1403
Shoulder symptom/complaint
L08 [2002000632]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
0
7
147
1500
—
Anastomosis to coronary artery from internal mammary artery, one distal anastamosis
FNA01 [2001303015]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.86%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
0
13
152
1507
—
—
—
—
—
0
5
138
1448
Methemoglobin/Hemoglobin.total in Arterial blood
2615-3 [3006217]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
0
5
138
1448
Localized oedema
R60.0 [45597193]
-1.0e+50
—
—
—
—
—
1.6e+00
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
cases:3.62%
controls:0.76%
0
8
152
1512
—
—
—
—
—
5
11
133
1442
Female infertility, unspecified
N97.9 [45582432]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
0
5
152
1515
—
—
—
—
—
0
9
138
1444
Other primary coxarthrosis
M16.1 [45591741]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
0
5
147
1502
—
lansoprazole; oral
A02BC03 [21600098]
7.2e-01
4.7e-01
—
—
—
1.0e+00
3.5e-01
cases:11.18%
controls:5.79%
cases:3.95%
controls:2.50%
—
—
—
—
—
—
cases:5.44%
controls:2.06%
cases:8.70%
controls:6.26%
17
88
135
1432
6
38
146
1482
—
—
—
8
31
139
1476
12
91
126
1362
Outlining of treatment with patient or their family members
SPAT1276 [2001700377]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
0
5
138
1448
Recording of ECG
SPAT1097 [2001700198]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.53%
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
0
8
152
1512
0
5
152
1515
—
—
—
—
—
cloxacillin; oral, parenteral
J01CF02 [21602854]
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:3.31%
controls:0.00%
—
—
—
—
—
—
—
—
5
0
146
1520
—
—
bimatoprost
S01EE03 [21603712]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.33%
cases:0.00%
controls:0.33%
—
—
—
—
—
—
cases:0.00%
controls:0.33%
cases:0.00%
controls:0.55%
0
5
152
1515
0
5
152
1515
—
—
—
0
5
147
1502
0
8
138
1445
acrivastine; oral
R06AX18 [21603518]
1.4e-01
—
-1.0e+50
—
—
—
1.6e-01
cases:5.26%
controls:4.61%
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
cases:5.07%
controls:4.34%
8
70
144
1450
—
0
6
152
1514
—
—
—
7
63
131
1390
Memory disturbance
P20 [2002000816]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.53%
cases:0.00%
controls:0.53%
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
0
8
152
1512
0
8
152
1512
—
—
—
0
5
147
1502
—
Medical abortion, complete or unspecified, without complication
O04.9 [45543909]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
0
10
152
1510
—
—
—
—
—
0
9
138
1444
insulin detemir; parenteral
A10AE05 [21600740]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
152
1515
—
0
13
151
1507
—
—
Malignant neoplasm of prostate
C61 [45547509]
—
1.2e+00
—
—
—
1.3e+00
1.1e+00
—
—
cases:3.29%
controls:0.99%
—
—
—
—
—
—
cases:3.40%
controls:1.00%
cases:4.35%
controls:1.45%
—
5
15
147
1505
—
—
—
5
15
142
1492
6
21
132
1432
Attendant Care Provider
3747A0650X [38004431]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
7
138
1446
Connective tissue diseases, rheumatoid arthritis and comparable disease
202 [2001600200]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.89%
0
11
152
1509
—
—
—
—
—
0
13
138
1440
Sensorineural hearing loss, bilateral
H90.3 [45576850]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
0
12
152
1508
—
—
—
0
11
147
1496
—
chloramphenicol
S01AA01 [21603554]
—
—
—
—
—
—
5.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.25%
controls:4.47%
—
—
—
—
—
—
10
65
128
1388
Dementia
P70 [2002000864]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
7
138
1446
Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture
546-2 [3024135]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
0
8
147
1499
—
Periodontitis pronounced
K05.31 [2000502729]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.62%
controls:0.76%
—
—
—
—
—
—
5
11
133
1442
Bicarbonate [Moles/volume] standard in Capillary blood
19231-0 [3004490]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
0
5
138
1448
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
—
—
—
—
—
—
5.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.25%
controls:4.27%
—
—
—
—
—
—
10
62
128
1391
Acute upper respiratory infection, unspecified
J06.9 [45562437]
1.2e+00
—
—
—
—
1.2e+00
2.0e-01
cases:5.26%
controls:1.58%
—
—
—
—
—
—
—
—
cases:3.40%
controls:1.06%
cases:5.80%
controls:4.82%
8
24
144
1496
—
—
—
—
5
16
142
1491
8
70
130
1383
Periapical abscess without sinus
K04.7 [45586692]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
7
138
1446
lovastatin; oral
C10AA02 [21601857]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
cases:0.00%
controls:0.86%
cases:0.00%
controls:0.89%
—
0
12
152
1508
—
—
—
0
13
147
1494
0
13
138
1440
erdosteine; oral
R05CB15 [21603394]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
152
1513
—
—
—
—
—
—
Acute subendocardial infarction unspecified coronary artery status
I21.49 [2000502437]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
6
138
1447
hydrocortisone; local oral
A01AC03 [21600036]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
0
6
147
1501
—
phenylephrine, combinations
R01BA53 [21603214]
1.8e-01
-1.0e+50
—
—
—
—
6.4e-01
cases:4.61%
controls:3.88%
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
cases:4.35%
controls:2.34%
7
59
145
1461
0
14
152
1506
—
—
—
—
6
34
132
1419
Split tooth for reasons other than trauma
K03.82 [2000502700]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
0
5
138
1448
Other specified special examinations
Z01.8 [45581003]
1.3e+00
1.6e+00
—
—
—
—
1.0e+00
cases:4.61%
controls:1.32%
cases:3.29%
controls:0.66%
—
—
—
—
—
—
—
—
cases:7.25%
controls:2.75%
7
20
145
1500
5
10
147
1510
—
—
—
—
10
40
128
1413
betamethasone
S02BA07 [21605169]
1.5e-01
7.1e-01
—
—
—
—
-3.5e-01
cases:5.92%
controls:5.13%
cases:3.95%
controls:1.97%
—
—
—
—
—
—
—
—
cases:4.35%
controls:6.06%
9
78
143
1442
6
30
146
1490
—
—
—
—
6
88
132
1365
carisoprodol; oral
M03BA02 [21604094]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
6
138
1447
acetylcysteine; inhalant, oral
R05CB01 [21603380]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
152
1515
—
—
—
—
—
—
SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: never
SMOKING-2-3-5 [2002330114]
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.64%
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
0
25
152
1495
0
5
152
1515
—
—
—
—
Angina pectoris, unspecified
I20.99 [2000502407]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
0
7
152
1513
—
—
—
—
0
5
147
1502
—
pH of Serum or Plasma
2753-2 [3018418]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.25%
controls:2.68%
—
—
—
—
—
—
10
39
128
1414
diclofenac
S01BC03 [21603641]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
0
5
138
1448
Digoxin [Moles/volume] in Serum or Plasma
14698-5 [3027456]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
0
5
138
1448
Phase of life problem adult
P25 [2002000820]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
0
5
138
1448
Short blood count panel - Blood
55429-5 [40758558]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.52%
controls:2.41%
—
—
—
—
—
—
9
35
129
1418
Assessment of need for aid
SPAT1229 [2001700330]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
0
12
138
1441
Diabetes, non-insulin-treated
215 [2001600211]
-1.0e+50
—
—
—
—
—
5.3e-01
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
cases:5.80%
controls:3.51%
0
5
152
1515
—
—
—
—
—
8
51
130
1402
metformin and sitagliptin
A10BD07 [21600772]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
0
5
152
1515
—
—
—
—
—
Coronary artery bypass surgery
11 [2002100102]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
152
1515
—
—
—
—
—
—
Hypothyroidism, unspecified
E03.9 [45537945]
—
—
—
—
—
—
6.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.62%
controls:2.00%
—
—
—
—
—
—
5
29
133
1424
Gonarthrosis [arthrosis of knee]
M17 [45601350]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
0
6
147
1501
—
Endoscopic polypectomy in colon
JFA15 [2001304850]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
9
138
1444
Valproate [Moles/volume] in Serum or Plasma
14946-8 [3009466]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
6
138
1447
piroxicam; ointment
M02AA07 [21604043]
4.3e-01
—
—
—
—
1.3e+00
7.5e-01
cases:9.21%
controls:6.18%
—
—
—
—
—
—
—
—
cases:4.76%
controls:1.33%
cases:7.97%
controls:3.92%
14
94
138
1426
—
—
—
—
7
20
140
1487
11
57
127
1396
INR in Blood by Coagulation assay
34714-6 [3032080]
—
—
1.4e+00
—
—
7.8e-01
7.5e-01
—
—
—
—
cases:3.29%
controls:0.86%
—
—
—
—
cases:3.40%
controls:1.59%
cases:11.59%
controls:5.85%
—
—
5
13
147
1507
—
—
5
24
142
1483
16
85
122
1368
Hematology
82 [38004501]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
0
8
152
1512
—
—
—
0
5
147
1502
—
Ear symptom/complaint other
H29 [2002000484]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
0
5
147
1502
—
ketoconazole; oral
J02AB02 [21603078]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
152
1515
—
—
—
—
—
—
levocabastine
S01GX02 [21605086]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
152
1510
—
—
—
—
—
—
Complex partial epileptic seizure with secondary generalization
G40.22 [2000502141]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
0
5
138
1448
Injection therapy, other than intramuscular or subcutaneous
SPAT1203 [2001700304]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
0
5
138
1448
tizanidine; oral
M03BX02 [21604116]
2.9e-01
3.5e-01
—
—
-1.0e+50
6.2e-01
4.7e-01
cases:17.11%
controls:13.42%
cases:4.61%
controls:3.29%
—
—
—
—
cases:0.00%
controls:0.46%
cases:6.80%
controls:3.78%
cases:18.84%
controls:12.66%
26
204
126
1316
7
50
145
1470
—
—
0
7
151
1513
10
57
137
1450
26
184
112
1269
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
—
—
—
—
—
—
3.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.62%
controls:2.48%
—
—
—
—
—
—
5
36
133
1417
bupivacaine, combinations
N01BB51 [21604240]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
0
5
147
1502
—
cough suppressants and expectorants
R05FB02 [21603442]
2.0e-01
-1.0e+50
—
—
—
—
8.7e-01
cases:4.61%
controls:3.82%
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
—
cases:4.35%
controls:1.86%
7
58
145
1462
0
11
152
1509
—
—
—
—
6
27
132
1426
levofloxacin
S01AE05 [43534860]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
0
11
138
1442
Sampling
SPAT1263 [2001700364]
6.7e-01
5.6e-01
—
—
—
1.0e+00
6.1e-01
cases:3.29%
controls:1.71%
cases:3.29%
controls:1.91%
—
—
—
—
—
—
cases:4.76%
controls:1.73%
cases:11.59%
controls:6.68%
5
26
147
1494
5
29
147
1491
—
—
—
7
26
140
1481
16
97
122
1356
escitalopram; oral
N06AB10 [21604718]
6.8e-01
—
—
—
-1.0e+50
1.1e+00
9.1e-01
cases:3.95%
controls:2.04%
—
—
—
—
—
—
cases:0.00%
controls:0.59%
cases:3.40%
controls:1.13%
cases:7.97%
controls:3.37%
6
31
146
1489
—
—
—
0
9
151
1511
5
17
142
1490
11
49
127
1404
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
—
9.0e-01
—
—
—
9.3e-01
6.5e-01
—
—
cases:3.95%
controls:1.64%
—
—
—
—
—
—
cases:4.76%
controls:1.92%
cases:18.12%
controls:10.32%
—
6
25
146
1495
—
—
—
7
29
140
1478
25
150
113
1303
Nail symptom/complaint
S22 [2002000987]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
0
5
138
1448
Dental caries
K02 [45552906]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
152
1515
—
—
—
—
—
—
lidocaine, combinations
N01BB52 [21604241]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
0
6
147
1501
—
Extensive structural and functional ultrasound examination of heart
FM1EE [2001303307]
—
2.3e+00
—
—
—
—
6.1e-01
—
—
cases:3.29%
controls:0.33%
—
—
—
—
—
—
—
—
cases:4.35%
controls:2.41%
—
5
5
147
1515
—
—
—
—
6
35
132
1418
Chronic asthma and similar chronic obstructive pulmonary diseases
203 [2001600201]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.38%
—
0
6
152
1514
—
—
—
—
0
20
138
1433
Erythrocytes [#/volume] in Cerebral spinal fluid
26454-9 [3027475]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
0
5
138
1448
Other allergic rhinitis
J30.3 [45538477]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
0
6
152
1514
—
—
—
—
—
0
6
138
1447
isotretinoin; oral
D10BA01 [21602320]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
6
138
1447
Severe depressive episode without psychotic symptoms
F32.2 [45557202]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.62%
controls:0.55%
—
—
—
—
—
—
5
8
133
1445
Cough
R05 [45606792]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.86%
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
0
13
152
1507
0
6
152
1514
—
—
—
—
—
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
-1.0e+50
1.6e+00
—
—
—
—
9.3e-01
cases:0.00%
controls:0.53%
cases:3.95%
controls:0.86%
—
—
—
—
—
—
—
—
cases:10.14%
controls:4.27%
0
8
152
1512
6
13
146
1507
—
—
—
—
14
62
124
1391
Health maint/preventive medicine
A98 [2002000231]
2.7e-01
5.4e-01
9.9e-01
—
1.8e+00
2.1e-01
8.4e-02
cases:8.55%
controls:6.64%
cases:9.21%
controls:5.59%
cases:3.29%
controls:1.25%
—
—
cases:3.97%
controls:0.66%
cases:9.52%
controls:7.83%
cases:25.36%
controls:23.81%
13
101
139
1419
14
85
138
1435
5
19
147
1501
—
6
10
145
1510
14
118
133
1389
35
346
103
1107
Acute laryngitis
J04.0 [45533538]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
0
5
138
1448
Resection of other vein
PHD99 [2001309496]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.69%
0
12
152
1508
—
—
—
—
—
0
10
138
1443
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.25%
controls:2.68%
—
—
—
—
—
—
10
39
128
1414
diclofenac, combinations; oral
M01AB55 [21603959]
1.3e+00
—
—
—
—
—
-1.0e+50
cases:3.29%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
5
14
147
1506
—
—
—
—
—
0
6
138
1447
Stroke/cerebrovascular accident
K90 [2002000617]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
0
5
138
1448
azithromycin; oral, parenteral
J01FA10 [21602978]
6.5e-01
2.8e-01
—
—
—
9.1e-01
7.5e-01
cases:19.08%
controls:10.92%
cases:3.95%
controls:3.03%
—
—
—
—
—
—
cases:6.80%
controls:2.85%
cases:18.84%
controls:9.91%
29
166
123
1354
6
46
146
1474
—
—
—
10
43
137
1464
26
144
112
1309
Conventional CABG
AA1 [2000200103]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
152
1512
—
—
—
—
—
—
Benign neoplasm: Rectum
D12.8 [45595734]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
0
5
138
1448
Demanding periodontal treatment
SDA04 [2001310329]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.35%
controls:1.31%
—
—
—
—
—
—
6
19
132
1434
Acute bronchitis, unspecified
J20.9 [45562445]
—
—
—
—
—
—
6.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.62%
controls:2.00%
—
—
—
—
—
—
5
29
133
1424
antibiotics in combination with other drugs
S01AA20 [21603571]
0.0e+00
—
—
—
—
1.0e+00
-4.3e-01
cases:4.61%
controls:4.61%
—
—
—
—
—
—
—
—
cases:3.40%
controls:1.26%
cases:4.35%
controls:6.54%
7
70
145
1450
—
—
—
—
5
19
142
1488
6
95
132
1358
Alzheimer disease with late onset
G30.1 [45552521]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
152
1511
—
—
—
—
—
—
Aortic (valve) insufficiency
I35.1 [45572087]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
0
8
152
1512
—
—
—
—
0
6
147
1501
—
benzathine phenoxymethylpenicillin; oral
J01CE10 [21602850]
-5.3e-02
3.7e-01
-1.0e+50
—
—
3.2e-01
-5.6e-02
cases:12.50%
controls:13.09%
cases:4.61%
controls:3.22%
cases:0.00%
controls:0.53%
—
—
—
—
cases:4.08%
controls:2.99%
cases:11.59%
controls:12.18%
19
199
133
1321
7
49
145
1471
0
8
152
1512
—
—
6
45
141
1462
16
177
122
1276
insulin aspart; parenteral
A10AD05 [21600733]
—
—
-1.0e+50
—
-1.0e+50
—
2.9e-01
—
—
—
—
cases:0.00%
controls:0.33%
—
—
cases:0.00%
controls:0.72%
—
—
cases:4.35%
controls:3.30%
—
—
0
5
152
1515
—
0
11
151
1509
—
6
48
132
1405
Fungus identified in Specimen by Culture
580-1 [3000494]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.62%
controls:0.96%
—
—
—
—
—
—
5
14
133
1439
dextromethorphan, combinations; oral
N07XX59 [43534835]
2.0e-01
-1.0e+50
—
—
—
—
8.7e-01
cases:4.61%
controls:3.82%
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
—
cases:4.35%
controls:1.86%
7
58
145
1462
0
11
152
1509
—
—
—
—
6
27
132
1426
Volume depletion
E86 [45581386]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
0
5
138
1448
dexamethasone and antiinfectives
S01CA01 [21603652]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
152
1509
—
—
—
—
—
—
COVID-19, virus not identified
U07.2 [45756094]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
6
138
1447
Acute tubulo-interstitial nephritis
N10 [45543856]
—
—
—
—
—
—
7.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.62%
controls:1.79%
—
—
—
—
—
—
5
26
133
1427
Fall on same level involving ice and snow
W00 [45756242]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
0
7
152
1513
—
—
—
—
—
indapamide; oral
C03BA11 [21601499]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.66%
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
0
10
152
1510
0
8
152
1512
—
—
—
—
0
6
138
1447
formoterol and budesonide
R03AK07 [21603281]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.33%
cases:0.00%
controls:0.46%
—
—
—
—
—
—
cases:0.00%
controls:0.33%
cases:0.00%
controls:0.48%
0
5
152
1515
0
7
152
1513
—
—
—
0
5
147
1502
0
7
138
1446
aciclovir; oral, parenteral
J05AB01 [21603131]
8.2e-01
—
—
—
—
—
5.7e-01
cases:3.95%
controls:1.78%
—
—
—
—
—
—
—
—
—
—
cases:5.80%
controls:3.37%
6
27
146
1493
—
—
—
—
—
8
49
130
1404
Supervision of normal first pregnancy
Z34.0 [45595500]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.59%
cases:0.00%
controls:0.39%
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
0
9
152
1511
0
6
152
1514
—
—
—
0
6
147
1501
—
Epilepsy
G40 [45595935]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
6
138
1447
Gynecological ultrasound examination as part of clinical examination
LX1AE [2001306815]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
0
11
138
1442
beclometasone; inhalant
R03BA01 [21603284]
7.8e-01
—
-1.0e+50
—
—
-1.0e+50
—
cases:3.95%
controls:1.84%
—
—
cases:0.00%
controls:0.39%
—
—
—
—
cases:0.00%
controls:0.73%
—
—
6
28
146
1492
—
0
6
152
1514
—
—
0
11
147
1496
—
chloramphenicol
S03AA08 [21605197]
—
—
—
—
—
—
5.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.25%
controls:4.47%
—
—
—
—
—
—
10
65
128
1388
Sexual health counselling
SPAT1308 [2001700409]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.89%
—
—
—
—
—
—
0
13
138
1440
orphenadrine, combinations
M03BC51 [21604113]
6.1e-01
-1.0e+50
—
—
—
-1.0e+50
8.1e-01
cases:4.61%
controls:2.57%
cases:0.00%
controls:0.59%
—
—
—
—
—
—
cases:0.00%
controls:0.53%
cases:7.97%
controls:3.72%
7
39
145
1481
0
9
152
1511
—
—
—
0
8
147
1499
11
54
127
1399
Chronic glaucoma with open ventricular angle
H40.13 [2000502335]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
6
138
1447
Excessive ear wax
H81 [2002000536]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
152
1511
—
—
—
—
—
—
Presence of external hearing-aid
Z97.4 [45542504]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
6
138
1447
Leukocytes [#/volume] in Urine
30405-5 [3018095]
-1.0e+50
—
—
—
—
—
5.3e-01
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
cases:5.80%
controls:3.51%
0
6
152
1514
—
—
—
—
—
8
51
130
1402
covid-19, RNA-based vaccine
J07BN01 [954934]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.53%
cases:0.00%
controls:0.46%
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
0
8
152
1512
0
7
152
1513
—
—
—
0
6
147
1501
—
dexamethasone; local oral
A01AC02 [21600035]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
152
1509
—
—
—
—
—
—
acetylsalicylic acid; oral, parenteral, rectal
N02BA01 [21604305]
—
—
-1.0e+50
—
—
1.2e+00
7.2e-01
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
cases:3.40%
controls:1.06%
cases:3.62%
controls:1.79%
—
—
0
5
152
1515
—
—
5
16
142
1491
5
26
133
1427
General counselling and advice on contraception
Z30.0 [45537624]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
6
138
1447
ticagrelor; oral
B01AC24 [40252640]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
6
138
1447
Other and unspecified symptoms and signs involving cognitive functions and awareness
R41.8 [45534452]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
0
5
152
1515
—
—
—
—
—
lymecycline; oral, parenteral
J01AA04 [21602802]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.89%
—
—
—
—
—
—
0
13
138
1440
nitrofurantoin; oral
J01XE01 [21603058]
1.9e+00
—
—
—
—
—
—
cases:3.29%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
5
8
147
1512
—
—
—
—
—
—
Lactate [Moles/volume] in Venous blood
2519-7 [3008037]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
0
5
138
1448
Small restoration
SFA00 [2001310357]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
152
1514
—
—
—
—
—
—
chlorphenamine, combinations
R06AB54 [21603468]
1.8e-01
-1.0e+50
—
—
—
—
6.4e-01
cases:4.61%
controls:3.88%
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
cases:4.35%
controls:2.34%
7
59
145
1461
0
14
152
1506
—
—
—
—
6
34
132
1419
Glaucoma suspect
H40.0 [45567051]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.76%
0
7
152
1513
—
—
—
—
—
0
11
138
1442
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
7.9e-01
—
—
—
-1.0e+50
—
4.8e-01
cases:3.29%
controls:1.51%
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
cases:14.49%
controls:9.50%
5
23
147
1497
—
—
—
0
6
151
1514
—
20
138
118
1315
haloperidol; oral, parenteral
N05AD01 [21604516]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
cases:0.00%
controls:0.34%
—
—
—
—
—
0
6
147
1501
0
5
138
1448
norethisterone and ethinylestradiol
G03AA05 [21602478]
5.2e-01
—
-1.0e+50
—
-1.0e+50
—
—
cases:3.29%
controls:1.97%
—
—
cases:0.00%
controls:0.53%
—
—
cases:0.00%
controls:0.33%
—
—
—
—
5
30
147
1490
—
0
8
152
1512
—
0
5
151
1515
—
—
Functional capacity evaluation
443351003 [40481051]
—
—
—
—
—
—
8.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.35%
controls:1.86%
—
—
—
—
—
—
6
27
132
1426
Body mass index
60621009 [4245997]
—
-4.1e-01
-1.0e+50
—
—
—
1.0e+50
—
—
cases:3.95%
controls:5.86%
cases:0.00%
controls:0.72%
—
—
—
—
—
—
cases:9.42%
controls:0.00%
—
6
89
146
1431
0
11
152
1509
—
—
—
13
0
125
1453
Personal history of diseases of the digestive system
Z87.1 [45542474]
1.1e+00
1.4e+00
—
—
—
—
6.1e-01
cases:3.29%
controls:1.12%
cases:3.29%
controls:0.86%
—
—
—
—
—
—
—
—
cases:10.14%
controls:5.78%
5
17
147
1503
5
13
147
1507
—
—
—
—
14
84
124
1369
medroxyprogesterone; oral, parenteral
G03DA02 [21602540]
9.9e-01
—
—
—
—
—
—
cases:3.29%
controls:1.25%
—
—
—
—
—
—
—
—
—
—
—
—
5
19
147
1501
—
—
—
—
—
—
felodipine; oral
C08CA02 [21601748]
5.6e-01
—
—
—
-1.0e+50
—
—
cases:3.95%
controls:2.30%
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
6
35
146
1485
—
—
—
0
7
151
1513
—
—
Osteoporosis, unspecified
M81.9 [45591963]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
152
1515
—
—
—
—
—
—
Trichilemmal cyst
L72.1 [45596386]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
0
8
138
1445
Laparoscopic hysterectomy
LCD04 [2001306586]
—
—
1.0e+50
—
—
—
—
—
—
—
—
cases:3.29%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
5
0
147
1520
—
—
—
—
Benign neoplasm: Skin of other and unspecified parts of face
D23.3 [45595740]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
0
5
138
1448
Prostate Specific Ag Free [Mass/volume] in Serum or Plasma
10886-0 [3005013]
—
—
—
—
—
—
8.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.80%
controls:2.55%
—
—
—
—
—
—
8
37
130
1416
Elevated blood-pressure reading, without diagnosis of hypertension
R03.0 [45553712]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
0
5
138
1448
rofecoxib; oral
M01AH02 [21603993]
2.8e-01
-1.0e+50
—
—
—
—
9.4e-01
cases:3.29%
controls:2.50%
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
cases:3.62%
controls:1.45%
5
38
147
1482
0
10
152
1510
—
—
—
—
5
21
133
1432
Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection
76080-1 [46235759]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
0
5
138
1448
alendronic acid and colecalciferol; oral
M05BB03 [21604160]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
152
1513
—
—
—
—
—
—
itraconazole; oral, parenteral
J02AC02 [21603081]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.31%
—
—
—
—
—
—
0
19
138
1434
natamycin; vaginal
G01AA02 [21602364]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
152
1513
—
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
36
151
2.81
6.23
3.0
1.6
—
—
—
0
0
64
373
2.24
5.38
5.5
4.2
—
—
—
0
0
58
342
2.13
4.60
3.9
2.1
2.90
3.06
mg/l
0.20
51
304
32
151
2.42
4.29
3.8
2.7
4.53
7.74
umol/l
1.19
27
131
36
201
2.04
3.18
2.7
2.1
—
—
—
0
0
45
272
1.93
3.18
5.1
3.5
405.12
313.07
ng/l
0.11
34
205
19
81
2.54
3.13
1.2
1.3
—
—
—
0
0
80
585
1.78
3.03
2.5
2.2
94.83
94.80
pmol/l
0.00
38
308
31
513
0.50
2.95
3.7
3.1
—
—
—
0
0
61
415
1.78
2.93
11.7
7.2
—
—
—
0
0
33
186
1.99
2.82
25.0
6.9
104.79
104.06
mmol/l
0.31
33
186
8
20
4.16
2.60
2.3
2.7
—
—
—
0
0
28
154
2.00
2.56
13.6
11.5
7.42
7.42
ph
0.10
16
94
62
439
1.70
2.52
3.6
2.9
7.66
7.87
mmol/l
0.12
49
367
80
614
1.64
2.34
16.8
6.8
1.21
1.21
mmol/l
0.08
74
566
18
87
2.21
2.28
5.9
10.0
—
—
—
0
0
37
232
1.79
2.28
5.8
3.0
0.79
0.82
mmol/l
0.75
32
219
5
9
5.70
2.23
1.2
4.3
—
—
—
0
0
28
163
1.88
2.17
3.2
5.6
0.96
1.05
mmol/l
1.40
23
146
10
37
2.82
2.11
1.1
4.3
1.28
4.19
ratio
—
5
21
16
77
2.20
2.05
1.0
1.2
—
—
—
0
0
95
777
1.59
2.02
15.7
10.8
5.13
4.13
e9/l
2.55
83
678
57
415
1.60
1.99
3.8
3.0
73.42
47.47
mg/l
0.37
35
278
21
116
1.94
1.90
3.9
2.5
2.79
6.19
ug/l
2.40
15
104
32
207
1.69
1.76
3.6
2.9
3.47
2.44
e6/l
0.29
15
100
112
1244
0.62
1.72
5.5
5.2
1.35
1.47
mmol/l
2.51
100
1154
83
674
1.51
1.71
16.5
7.7
1.21
1.21
mmol/l
0.02
71
590
57
429
1.53
1.68
4.4
3.6
12.11
7.77
mg/mmol
0.32
34
271
19
108
1.87
1.59
40.2
9.3
—
—
—
0
0
94
791
1.49
1.58
13.9
5.5
7.37
6.56
mmol/l
2.30
89
749
86
711
1.48
1.58
12.5
6.9
0.22
0.18
e9/l
1.29
74
625
22
132
1.78
1.56
25.7
3.3
0.66
2.06
mmol/l
1.52
17
111
51
380
1.51
1.56
4.8
3.0
0.28
0.38
e6/l
0.42
40
279
11
51
2.25
1.54
2.9
2.0
0.38
6.41
ug/l
0.55
11
44
5
15
3.41
1.53
1.4
1.3
—
—
—
0
0
116
1025
1.56
1.50
15.3
8.2
77.99
77.87
u/l
0.01
110
965
56
430
1.48
1.47
6.3
4.0
7.40
7.39
ph
0.15
37
300
9
39
2.39
1.46
3.3
1.9
23.94
24.29
mmol/l
—
9
39
5
16
3.19
1.45
4.0
1.5
3.34
7.48
u/ml
—
5
16
108
1197
0.66
1.43
4.4
4.4
1.63
1.27
mmol/l
4.00
95
1103
15
82
1.92
1.41
15.9
11.6
94.34
92.82
%
0.62
15
82
7
29
2.48
1.41
2.1
1.2
—
106.00
—
0
5
22
137
1.71
1.39
25.9
3.4
7.35
7.40
ph
—
10
91
5
17
3.00
1.37
1.4
1.2
—
—
—
0
0
16
93
1.81
1.27
1.3
2.8
—
—
—
0
0
6
25
2.46
1.25
3.7
1.9
87.27
91.58
%
—
6
25
25
166
1.61
1.25
1.4
1.3
—
—
—
0
0
64
517
1.41
1.25
2.3
2.2
—
—
—
0
0
82
693
1.40
1.23
12.6
6.1
0.67
0.58
e9/l
2.08
69
601
83
703
1.40
1.22
12.6
6.2
2.29
1.86
e9/l
0.58
72
621
24
345
0.64
1.20
1.4
1.4
—
—
—
0
0
76
636
1.39
1.19
26.7
13.3
1.31
1.27
inr
0.24
63
516
82
696
1.39
1.18
12.6
6.2
0.05
0.04
e9/l
0.67
69
600
12
65
1.92
1.17
3.3
4.0
36.99
36.97
°c
0.16
12
65
56
447
1.40
1.16
4.6
3.2
17.55
199.85
e6/l
0.68
44
344
41
310
1.44
1.14
1.4
1.3
0.51
1.82
u/ml
1.48
12
81
118
1272
0.68
1.13
6.2
5.9
2.48
2.70
mmol/l
1.89
107
1181
74
621
1.37
1.13
4.5
3.0
119.72
112.84
ug/l
0.10
69
588
7
33
2.17
1.07
2.1
1.2
—
—
—
0
0
14
83
1.76
1.05
1.4
1.5
—
—
—
0
0
10
54
1.91
0.99
3.5
2.5
—
—
—
0
0
7
36
1.99
0.98
1.0
1.1
—
—
—
0
0
26
185
1.49
0.98
1.5
1.2
—
—
—
0
0
117
1253
0.71
0.92
5.3
5.3
4.35
4.63
mmol/l
2.36
110
1168
17
111
1.60
0.92
2.3
3.2
80.96
71.53
e9/l
0.36
11
87
70
599
1.31
0.88
17.1
11.9
0.00
0.00
e9/l
0.51
55
481
48
389
1.34
0.88
1.9
1.7
17.00
21.94
nmol/l
2.10
38
335
23
165
1.46
0.84
1.7
1.6
—
—
—
0
0
6
32
1.91
0.82
1.3
4.0
12.50
40.30
u/ml
—
6
32
6
32
1.91
0.82
3.8
1.7
7.72
8.16
kpa
—
6
32
98
887
1.30
0.77
6.4
4.6
—
4506.47
—
0
17
60
512
1.28
0.75
5.3
3.9
32.39
106.87
e6/l
1.16
48
361
20
143
1.46
0.75
1.9
1.5
—
—
—
0
0
5
25
2.03
0.73
102.8
2.2
67.20
59.50
%
—
5
25
17
118
1.50
0.73
2.5
2.0
0.00
0.00
estimate
—
6
27
53
449
1.28
0.69
13.0
5.7
—
—
—
0
0
114
1212
0.76
0.69
6.0
5.2
6.28
5.90
mmol/l
1.93
105
1132
38
308
1.31
0.69
3.6
1.8
1.29
1.42
mg/l
0.13
31
254
34
418
0.76
0.68
4.9
3.3
0.00
0.01
estimate
—
10
118
7
43
1.66
0.68
1.1
1.2
—
—
—
0
0
48
563
0.78
0.67
5.8
3.9
0.00
0.02
estimate
0.50
11
123
12
80
1.54
0.62
1.8
1.2
425.13
408.36
u/ml
0.02
12
74
8
51
1.60
0.61
1.9
2.7
—
—
—
0
0
23
176
1.36
0.61
1.5
1.5
—
—
—
0
0
33
401
0.77
0.61
6.0
5.6
4.80
2.91
ug/l
0.26
28
364
0
20
0.00
0.61
0.0
2.4
—
—
—
0
0
0
22
0.00
0.60
0.0
1.5
—
—
—
0
0
49
421
1.24
0.56
3.6
2.2
—
—
—
0
0
24
189
1.32
0.54
1.8
1.4
194.29
584.31
titre
—
7
51
33
272
1.27
0.53
1.7
1.7
428.36
469.31
pmol/l
0.37
28
234
6
40
1.52
0.52
1.0
1.1
—
—
—
0
0
34
404
0.80
0.52
7.5
4.0
0.00
0.02
estimate
0.50
13
129
19
243
0.75
0.51
2.5
3.2
0.63
0.75
ug/l
0.44
12
164
34
284
1.25
0.50
1.9
1.3
2.38
2.50
g/l
0.13
21
174
38
322
1.24
0.49
4.8
4.0
—
0.29
—
0
7
28
230
1.27
0.47
2.2
1.7
1577.78
1197.53
nmol/l
0.64
18
180
7
51
1.39
0.44
1.0
1.1
—
—
—
0
0
32
269
1.24
0.44
1.3
1.3
26.55
35.67
iu/ml
0.40
12
82
29
241
1.25
0.44
1.2
1.3
6.70
10.83
u/ml
—
10
90
8
58
1.40
0.42
1.5
1.2
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
258.00
—
0
9
67
727
0.86
0.37
5.7
3.9
0.00
0.00
estimate
-0.00
12
137
16
127
1.29
0.35
1.1
1.3
—
—
—
0
0
14
109
1.31
0.35
1.2
1.1
—
—
—
0
0
6
44
1.38
0.35
2.0
3.0
1.45
1.65
mmol/l
—
6
44
26
303
0.83
0.33
9.2
5.2
—
—
—
0
0
52
477
1.14
0.27
3.7
3.5
2.39
2.35
mmol/l
1.27
47
435
11
136
0.79
0.24
1.9
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
2.11
—
0
6
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.9
—
7.20
—
0
10
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
42
387
1.12
0.20
3.1
3.1
—
0.20
—
0
10
19
165
1.17
0.20
1.3
1.4
—
—
—
0
0
64
604
1.10
0.20
3.7
2.8
—
—
estimate
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
7
59
1.20
0.18
2.3
1.8
—
—
—
0
0
70
733
0.92
0.17
5.4
4.0
0.00
11.52
estimate
0.50
14
141
5
69
0.72
0.17
2.4
1.5
—
—
—
0
0
10
117
0.84
0.13
1.3
1.3
—
—
—
0
0
61
585
1.07
0.12
4.8
3.6
6.37
6.20
ph
0.49
36
337
128
1299
0.91
0.11
23.5
14.6
—
—
—
0
0
72
741
0.95
0.09
5.4
4.0
0.00
0.00
estimate
-0.00
14
136
17
156
1.10
0.08
7.3
4.3
3.54
54.67
ug/l
0.60
12
126
52
538
0.95
0.08
6.1
4.2
22.88
33.53
ng/l
0.69
41
373
6
71
0.84
0.08
1.3
1.1
—
—
—
0
0
6
74
0.80
0.08
1.0
1.7
—
—
—
0
0
54
557
0.95
0.07
2.2
2.0
1.62
1.29
mmol/l
2.01
42
475
19
203
0.93
0.06
1.4
1.8
—
—
—
0
0
116
1171
0.96
0.04
6.9
5.5
1.90
1.92
mu/l
0.07
107
1089
12
112
1.08
0.03
4.9
4.6
0.40
0.57
%
—
5
35
29
282
1.04
0.02
4.1
3.0
2.49
2.46
mmol/l
0.53
24
252
31
318
0.97
0.02
5.2
4.3
1.02
1.02
kg/l
0.12
25
215
98
986
0.98
0.00
5.6
4.5
14.99
14.80
pmol/l
0.31
92
911
12
119
1.01
0.00
6.3
5.1
0.00
0.26
%
—
5
31
12
121
0.99
0.00
5.0
4.6
0.20
1.12
%
—
5
41
126
1257
1.01
0.00
34.2
16.8
30.05
23.67
mg/l
1.25
113
1056
42
425
0.98
0.00
5.0
3.1
—
—
—
0
0
0
6
0.00
0.00
0.0
6.3
—
44.50
—
0
6
0
6
0.00
0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
2.5
—
12153.67
—
0
6
5
49
1.02
0.00
8.4
14.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
32.60
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
9
95
0.94
-0.00
11.1
3.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
121.11
—
0
9
0
9
0.00
-0.00
0.0
1.2
—
78.56
—
0
9
0
8
0.00
-0.00
0.0
1.3
—
128.67
—
0
8
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
1.01
—
0
7
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.2
—
15.22
—
0
9

Mortality – FinRegistry

↥

Association

Association between endpoint D3_NEFELOF and mortality.

Females

Parameter HR [95% CI] p-value
D3_NEFELOF 2.605 [2.14, 3.17] < 0.001
Birth year 0.995 [0.99, 1.0] 0.251

During the follow-up period (1.1.1998 — 31.12.2019), 196 out of 545 females with D3_NEFELOF died.

Males

Parameter HR [95% CI] p-value
D3_NEFELOF 2.144 [1.72, 2.67] < 0.001
Birth year 0.985 [0.98, 0.99] 0.002

During the follow-up period (1.1.1998 — 31.12.2019), 232 out of 494 males with D3_NEFELOF died.

Mortality risk

Mortality risk for people of age

years, who have D3_NEFELOF.

N-year risk Females Males
1 0.214% 0.381%
5 1.519% 2.293%
10 3.579% 5.701%
15 7.055% 11.045%
20 12.424% 18.225%

Relationships between endpoints

↥

Index endpoint: D3_NEFELOF – Nezelof syndrome

GWS hits: 1

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data